Drug-induced cell cycle modulation leading to cell-cycle arrest, nuclear mis-segregation, or endoreplication
© Sakaue-Sawano et al; licensee BioMed Central Ltd. 2011
Received: 5 July 2010
Accepted: 13 January 2011
Published: 13 January 2011
Cancer cell responses to chemotherapeutic agents vary, and this may reflect different defects in DNA repair, cell-cycle checkpoints, and apoptosis control. Cytometry analysis only quantifies dye-incorporation to examine DNA content and does not reflect the biological complexity of the cell cycle in drug discovery screens.
Using population and time-lapse imaging analyses of cultured immortalized cells expressing a new version of the fluorescent cell-cycle indicator, Fucci (F luorescent U biquitination-based C ell C ycle I ndicator), we found great diversity in the cell-cycle alterations induced by two anticancer drugs. When treated with etoposide, an inhibitor of DNA topoisomerase II, HeLa and NMuMG cells halted at the G2/M checkpoint. HeLa cells remained there, but NMuMG cells then overrode the checkpoint and underwent nuclear mis-segregation or avoided the checkpoint and entered the endoreplication cycle in a drug concentration dependent manner. In contrast, an inhibitor of Cdk4 led to G1 arrest or endoreplication in NMuMG cells depending upon the initial cell-cycle phase of drug exposure.
Drug-induced cell cycle modulation varied not only between different cell types or following treatment with different drugs, but also between cells treated with different concentrations of the same drug or following drug addition during different phases of the cell cycle. By combining cytometry analysis with the Fucci probe, we have developed a novel assay that fully integrates the complexity of cell cycle regulation into drug discovery screens. This assay system will represent a powerful drug-discovery tool for the development of the next generation of anti-cancer therapies.
Effective anticancer agents preferentially kill cancer cells, and many anticancer drugs directly induce DNA damage and/or inhibit DNA repair pathways. In normal cells, in response to the DNA damage induced by anticancer drugs, a complex signaling network is activated to prevent the replication of damaged DNA and the transmission of damage-related alterations in DNA sequences to the next generation of cells . In contrast, cancer cells generally have defects in many of these pathways including factors regulating cell-cycle checkpoints. Such cells continue to divide in the face of widespread DNA damage, and this ultimately leads to cancer cell death. However, cancer cell responses to anticancer drugs vary [2, 3]. While some of the defects common to cancer cells enhance their sensitivity to drugs, other changes found in malignantly transformed cells increase their chemotherapy resistance. Additionally, environmental factors can affect the cellular response to anticancer drugs. Furthermore, there are several well-described cell-cycle variations that eukaryotic cells can exhibit. One common variant is the endoreplication cycle [4–11], in which cells increase their genomic DNA content without dividing. In order to fully integrate the complexity of the cell cycle into drug discovery screens, it is imperative to take a multifaceted approach, combining conventional cytometry analysis with a new technique that allows for visualizing the cell cycle progression of individual cells in real time.
Cell cycle progression is dependent upon the coordinated regulation of ubiquitination, and we harnessed this system to develop a genetically encoded indicator of cell cycle progression: Fucci (F luorescent U biquitination-based C ell C ycle I ndicator) . The original Fucci probe was generated by fusing mKO2 (monomeric Kusabira Orange2) and mAG (monomeric Azami Green) to the ubiquitination domains of human Cdt1 and Geminin, respectively. These two chimeric proteins, mKO2-hCdt1(30/120) and mAG-hGem(1/110), accumulate reciprocally in the nuclei of transfected cells during the cell cycle, labeling the nuclei of G1 phase cells orange and those of cells in S/G2/M phase green. Thus, they function as G1 and S/G2/M markers, respectively. We previously injected HeLa and NMuMG (normal murine mammary gland) cells constitutively expressing Fucci into the mammary fat pad of nude mice, to monitor changes in the cell cycle profiles of the foreign cells . Interestingly, while HeLa/Fucci cells replicated and began to spread metastatically, NMuMG/Fucci cells stopped proliferating.
Generation of Fucci2 constructs
We wished to develop new Fucci derivatives with different fluorescent properties, and, towards that end, we used a yellowish green monomeric variant of Aequorea green fluorescent protein (GFP) (mVenus) [13, 14] and a red monomeric fluorescent protein (mCherry) . mCherry and mVenus were substituted for mKO2 and mAG in the original Fucci constructs to generate mCherry-hCdt1(30/120) and mVenus-hGem(1/110), respectively (Additional file 1A). The new Fucci derivative was named "Fucci2." This particular combination of fluorophores provides better color contrast than that of Fucci (Additional file 1B). Additionally, the fluorescent characteristics of the widely used fluorophore enhanced GFP (EGFP) are able to be spectrally distinguished from those of Fucci2. This will facilitate imaging experiments where cell cycle progression is monitored in parallel with protein subcellular localization and/or signaling events.
To generate cell lines stably expressing Fucci2, lentiviral vectors were used for co-transduction of mCherry-hCdt1(30/120) and mVenus-hGem(1/110) in HeLa cells (HeLa/Fucci2). The mVenus fluorescence disappeared rapidly in late M phase and the red fluorescence of mCherry became detectable in early G1 phase; during the G1/S transition both fluorophores were present generating orange fluorescence (Additional files 1C and 2). HeLa/Fucci2 cells were divided into red-, orange-, and yellowish green-emitting populations (Additional file 1D), and their DNA contents were analyzed following Hoechst33342 staining. Yellowish green and orange cells had fully- and partially-replicated complements of DNA, respectively (Additional file 1E). We have also made a stable transformant constitutively expressing Fucci2 using normal murine mammary gland (NMuMG) cells (NMuMG/Fucci2) (Additional file 3).
To analyze cell cycle progression in culture, we used two complementary approaches. First, we collected a large number of cells that had been treated with varying concentrations of drug for different periods of time, and we stained their nuclei with Hoechst 33342 or 4',6-diamidino-2-phenylindole (DAPI). The number of cells in G1, G1/S, and S/G2/M phases were counted, and we quantified the DNA content of individual cells. For these large-scale analyses we used a fluorescence-activated cell sorter (FACS) and CELAVIEW RS100 (Olympus). The latter is a drug-screening platform designed for fully automated image acquisition and data analysis [16, 17]. In addition to cytometry functions for analyzing large data sets, the CELAVIEW system links acquired images with relevant cellular and biochemical information [18–20]. Alternatively, we used time-lapse imaging to monitor a relatively small number of live cells using an LCV100 (Olympus), a computer-assisted fluorescence microscopy system, which can monitor up to 8 cell culture dishes containing different concentrations of drugs under stabilized conditions over an extended period of time.
Additional file 4: Time-lapse imaging of Fucci2-expressing HeLa cells during etoposide treatment. HeLa/Fucci2 cells were grown on a glass-bottom dish and time-lapse imaging was performed using an LCV100. Cells were treated with 1 μM etoposide. Cells at 4 different positions were imaged every 20.5 m. Playback speed is 7,000 × real time. Total imaging time = 49 h. Most cells were arrested at the G2 DNA checkpoint (yellowish green). (MOV 1 MB)
In contrast, treatment of cells with 10 μM etoposide for 24 h produced a substantial number of NMuMG/Fucci2 cells with large, clear, and red nuclei (Figure 3D, right) rather than fragmented nuclei. We initially hypothesized that these cells had undergone G1 cell cycle arrest, but analysis of cells by FACS demonstrated a large population of cells with red nuclei with double the DNA content of normal cells (4C) (Figure 3E, right, an open arrow). Additionally, by time-lapse imaging we frequently observed NMuMG/Fucci2 cell nuclei progress from yellowish green to red without undergoing cell division (Additional file 6). No cellular features consistent with M phase were seen, including nuclear envelope breakdown and chromosome condensation, during the yellowish green-to-red color conversion. The presence of a large population of tetraploid cells suggests a transition from the mitotic to endoreplication cycles (Figure 1C), characterized by increases in cellular DNA content achieved by bypassing mitosis and cytokinesis. Gallery views of images of three data populations with varied DNA content are shown in the two-dimensional scatter plots created by CELAVIEW (Figure 3F, right and Figure 5C), demonstrating that each cell carrying the large red nucleus was tetraploid. We next monitored NMuMG/Fucci2 cells for an extended time period up to 96 h in the presence of 10 μM etoposide. During the period, most cells underwent only one round of DNA endoreplication generating large red nuclei, confirming that cells remained tetraploid at the end of the observation period (96 h).
Although etoposide predominantly affects the G2 to M transition, we wished to examine an additional anti-cancer therapeutic. We selected the cell-permeable Cdk4 inhibitor (2-bromo-12,13-dihydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione)  for further study with cells expressing Fucci2. This drug inhibits the growth of tumor cells (HCT-116 and NCI-H460 cells) with an IC50 <3.0 μM by blocking Rb phosphorylation and inducing G1 cell cycle arrest.
Tumor cells stably transfected with fluorescent proteins enable scientists to visualize many important aspects of cancer in real time at the single cell level. For example, transfected tumor cells have been visualized either through surgically created chronic-transparent windows or directly through the opened skin of living animals . This intravital imaging provides a powerful tool for observing cancer initiation and progression and evaluating the efficacy of candidate cancer drugs in vivo. On the other hand, assays using tumor cells grown in culture provide reliable information about cancer mechanisms, and are amenable to automated high-throughput screening [16–20]. Using a modified fluorescent indicator of cell cycle progression (Fucci2) and cultured immortalized cells, we investigated the mechanism(s) by which anticancer drugs modulate the cell cycle. While population analysis provided statistical data, time-lapse high-resolution imaging analysis allowed us to explore the processes of cell cycle alteration in great detail. Drug-induced cell cycle modulation varied between different cell types or following treatment with different drugs, but, intriguingly, differences were observed between cells treated with different concentrations of the same drug or following drug addition during different phases of the cell cycle (Figure 1).
Three different fates await NMuMG/Fucci2 cells at the G2/M checkpoint after exposure to etoposide. At low concentrations of the drug, cells halt their cell cycle at the checkpoint. At intermediate concentrations, cells override the checkpoint and undergo nuclear mis-segregation. At high concentrations, cells avoid the checkpoint and enter the endoreplication cycle. Endoreplication may render cells resistant to conditions that induce DNA damage, possibly because they have several copies of each gene and do not need to segregate their chromosomes . From a clinical perspective, the tendency of high concentrations of etoposide to induce endoreplication in NMuMG cells may provide insight into the persistence of disease and development of chemotherapy resistance.
When cells are treated with drugs that affect the cell cycle, drug concentration is an important parameter affecting the cellular response. However, other factors including environmental factors may be critical. A previous study showed that hematopoietic cells treated with etoposide halt their cell cycle at G2/M or experience nuclear mis-segregation in the presence or absence of hematopoietic cytokines, respectively . Also, asymmetric cell division may generate different vulnerabilities to drugs. We observed that cell division produced two daughter cells with different fates in the presence of 1 μM etoposide; one underwent nuclear mis-segregation and the other entered the endoreplication cycle (Figure 6C). This observation excludes the possibility that the diversity of drug response results from inherent heterogeneity of the cell lines.
Mammalian megakaryocytes and trophoblast giant cells undergo endoreplication to reach DNA ploidies with a DNA content >1,000-fold higher than that of a normal diploid cell [4, 5, 7–9]. We isolated megakaryocytes and trophoblast giant cells from Fucci transgenic mouse lines, and successfully imaged the endoreplication cycles in these cell types cultured on a coverslip (A. S.-S, and A. M. unpublished results); the nuclei changed color alternately many times between green and red while enlarging. This observation verifies that oscillations in ubiquitination involving the SCFSkp2 and APCCdh1 complexes function during the endoreplication cycle, and Fucci technology allows for the visualization of endoreplication [31–34]. In contrast to the developmentally programmed endoreplication , most of the NMuMG/Fucci2 cells treated with etoposide experienced endoreplication only once, stably remaining tetraploid during our observation period of ≤4 days. Although it is known that anticancer drugs induce endoreplication to generate polyploidy in a variety of cell types, the predominant accumulation of tetraploid cells was also reported to result from inhibition of DNA topoisomerase II in other biological systems . Conventional cell cycle analysis that only quantifies dye-incorporation using FACS may misinterpret this long-lasting tetraploid state as G2 arrest. The information provided by the Fucci probes regarding the cell cycle phase allowed us to identify the single-round of endoreplication in these cells. Although a single round of endoreplication was the principal outcome in this study, a small fraction of the NMuMG cells was observed to go through multiple endoreplication cycles in the presence of 1 - 3 μM etoposide (Figure 1C, Additional files 8 - 11).
Fucci allows for visualizing cell-cycle progression in real time at the single cell level. Combined with information of DNA content obtained by cytometry analysis, Fucci technology can reveal complex aspects of drug-induced cell cycle alteration(s). Importantly, the technology becomes more powerful with long-term time-lapse imaging experiments. This dynamic data will advance our understanding of how individual cells respond to a drug. In our time-lapse imaging experiments where NMuMG/Fucci2 cells were continuously treated with 1 - 3 μM etoposide, for example, nuclear mis-segregation and endoreplication were mutually exclusive; we did not see any transition from one to the other. Although it was reported that chromosomes were condensed during formation of endopolyploid cells [4, 24], the endoreplication observed in the present study lacked all vestiges of mitosis, including chromosome condensation, nuclear envelope breakdown, and the reorganization of microtubules that builds the spindle. The other finding made by time-lapse imaging was that NMuMG/Fucci2 cells entered the endoreplication cycle if they had been in late G1 phase when the Cdk4 inhibitor was added to the medium; otherwise, the cells exposed to the drug showed G1 cell-cycle arrest. These features could not be elucidated by conventional cell cycle analysis using fixed cell samples.
Fluorescence imaging of stably transformed Fucci2-expressing cells in culture will provide reliable pharmaco-dynamic readouts for the proliferation and death of cancer cells. Through full integration of statistical and image data, our multifaceted assay system represents a validated strategy for characterization of drugs that modulate the cell cycle for anticancer drug screening and for cell toxicity studies.
A complete understanding of the factors regulating cell cycle progression is essential for the generation of new anti-cancer agents, but the information gained from using existing reagents is becoming increasingly limited. We recently developed a novel genetically encoded indicator of cell cycle progression, Fucci (Fluorescent Ubiquitination-based Cell Cycle Indicator) that exploits the regulation of cell cycle dependent ubiquitination. In the Fucci technique, cells are genetically modified to express the G1 marker Cdt1 and the S/G2/M marker Geminin fused to orange and green fluorescent tags, respectively. As a result, actively replicating cell nuclei in S/G2/M phases exhibit green fluorescence, while nuclei that are in G1 and not yet actively dividing fluoresce orange. In this paper, we describe a new Fucci derivative, Fucci2, which utilizes red and yellowish green fluorescent tags. Using cultured immortalized cells (HeLa and NMuMG cells) that constitutively express Fucci2, we identify several possibly significant variations in the cell cycle that cells exposed to anticancer drugs (inhibitors of DNA topoisomerase II or Cdk4) can undergo. Interestingly, Drug-induced cell cycle modulation varied not only between different cell types or following treatment with different drugs, but also between cells treated with different concentrations of the same drug or following drug addition during different phases of the cell cycle. Importantly, these findings would be missed by conventional cytometry analysis that only quantifies dye-incorporation to examine DNA content. By combining cytometry analysis with the Fucci2 probe, we have developed a novel assay that fully integrates the complexity of cell cycle regulation into drug discovery screens. This assay system will represent a powerful drug-discovery tool for the development of the next generation of anti-cancer therapies.
cDNA encoding mCherry (kindly provided by Dr. R.Y. Tsien)  and mVenus  were amplified using primers containing 5'-EcoRI and 3'-NotI sites, and digested products were substituted for the mKO2 gene in mKO2-hCdt1(30/120) [DDBJ/EMBL/GenBank, AB370332] in pCSII-EF vector  and the mAG gene in mAG-hGem(1/110) [DDBJ/EMBL/GenBank, AB370333] in pCSII-EF vector, respectively. The sequences reported in this paper have been deposited in the DDBJ/EMBL/GenBank data-base [AB512478, mCherry-hCdt1(30/120); AB512479, mVenus-hGeminin(1/110)].
HeLa cells (a subclone of HeLa.S3 cells provided by Dr. Mikoshiba) were grown in DMEM supplemented with 10% fetal bovine serum and penicillin/streptomycin. Mouse NMuMG breast epithelial cells (ATCC; CRL-1636) were grown in DMEM (High glucose) supplemented with 10% fetal bovine serum, penicillin/streptomycin, and 10 μg/ml of insulin (Sigma: I0516). Etoposide (Cat. E1383) and Cdk4 inhibitor (Cat. 219476) were purchased from Sigma and Calbiochem, respectively.
Replication-defective, self-inactivating lentiviral vectors were used . The CSII-EF-MCS vector encoding mCherry-hCdt1(30/120) or mVenus-hGem(1/110) was co-transfected with the packaging plasmid (pCAG-HIVgp), and the VSV-G- and Rev-expressing plasmid (pCMV-VSV-G-RSV-Rev) into 293T cells. High-titer viral solutions were prepared and used for transduction into HeLa cells or NMuMG cells. Stable transformants were established by diluting cells by single-cell cloning or by FACS.
Hoechst 33342 solution (56 μl of 1 mg/ml stock) (DOJINDO, Kumamoto, Japan) was added to a 10-cm dish containing HeLa/Fucci2 or NMuMG/Fucci2 cells. After incubation for 30 min, cells were harvested and analyzed using a FACSAria II (BD Bioscience, San Jose, CA). mVenus was excited by a 488-nm laser line (laser diode) and its emission was collected through 515/20BP; mCherry was excited by a 532-nm laser line (diode-pumped solid state laser) and its emission was collected through 610/20 BP. Hoechst 33342 was excited by a UV Laser at 355 nm, and its emission was collected through 405/20 BP. The data were analyzed using FlowJo software (Tree Star).
Time-Lapse Imaging Cultured Cells
Cells stably expressing Fucci2: mCherry-hCdt1(30/120) and mVenus-hGem(1/110) were grown on 35-mm glass-bottom dishes in phenol red-free Dulbecco's modified Eagle's medium containing 10% fetal bovine serum (FBS). Cells were subjected to long-term, time-lapse imaging using a computer-assisted fluorescence microscope (Olympus, LCV100) equipped with an objective lens (Olympus, UAPO 40X/340 N.A. = 0.90), a halogen lamp, a red LED (620 nm), a CCD camera (Olympus, DP30), differential interference contrast (DIC) optical components, and interference filters. For fluorescence imaging, the halogen lamp was used with a 500AF25 excitation filter, a 525DRLP dichroic mirror, and a 545AF35 emission filter for observing mVenus, and a 565WB20 excitation filter, a 595DRLP dichroic mirror, and a 635DF55 emission filter for observing mCherry. For DIC imaging, the red LED was used with a filter cube containing an analyzer. As the components of the Fucci system are not bound tightly to chromatin, they are detached from dying cells as all dying cell membranes become permeable; we counted the number of cells lacking Fucci signals for measuring cell death. Image acquisition and analysis were performed using MetaMorph 6.37 and 22.214.171.124 software (Universal Imaging, Media, PA), respectively. Movies were assembled using Quick Time software.
HeLa/Fucci2 and NMuMG/Fucci2 cells were plated in 96-well polystyrene plates (Corning, Cat. 3596) at 1,200 cells/100 μl/well and 1,000 cells/100 μl/well, respectively, and grown in a CO2 incubator. 24 h later, the medium was changed to 150 μl of fresh medium containing 0 - 10 μM of etoposide or Cdk4 inhibitor. The plates were then incubated for 0, 12, 36 or 48 h. DMSO (0.1%) was used as a vehicle. Cells were washed with phosphate-buffered saline without divalent cations (PBS(-)), fixed with 100 μl of 4% paraformaldehyde in PBS(-) for 20 min at room temperature, stained with 1 μg/ml of DAPI (Roche: Cat. 10236276001) for 10 min at room temperature, and washed with PBS(-) twice. The wells were filled with 150 μl of PBS for observation using the CELAVIEW (OLYMPUS: RS100) instrument, which can scan multiple fields of multiple wells in a plate, and quantitatively analyze each cell in the images by extracting information on the spatial distribution of fluorescently labeled components. DAPI, mVenus, and mCherry were fluorescently detected with U-MNUA2 (OLYMPUS, ex: BP360-370, em: BA420-460), YFP-2427A (Semrock, ex: FF01-500/24, em: FF01-542/27) and U-MWIY2 (OLYMPUS, ex: BP545-580, em: BA610IF), respectively. Fifty-six images at different locations in each well were acquired using a CCD camera (ORCA-AG, Hamamatsu Photonics) through LUCPLFLN20X (OLYMPUS) objective lens.
Distribution of materials
Stable cell lines; HeLa/Fucci2 and NMuMG/Fucci2 cells will be distributed from the RIKEN BioResource Center Cell Bank http://www.brc.riken.go.jp/lab/cell/english/.
Acknowledgements and Funding
The authors thank Drs. H. Masai, T. Imamura and S. Sugano for valuable discussion and K. Kondo, Y. Watanabe (Olympus) and T. Tajima (BSI Olympus Collaboration Center) for technical assistance. mCherry plasmid was kindly provided by Dr. R.Y. Tsien. Lenti viral vectors were kindly provided by Dr. H. Miyoshi. This work was supported by Grant in Aid for Scientific Research on Innovative Areas "Fluorescence Live imaging" and "Cell Fate" of The Ministry of Education, Culture, Sports, Science, and Technology, Japan, Japan MEXT Grant in Aid for Scientific Research on priority areas and Research Program of Innovative Cell Biology by Innovative Technology (Cell Innovation).
- Weinberg RA: The biology of CANCER. 2007, Garland Science, Taylor & Francis Group, NYGoogle Scholar
- Longley DB, Johnston PG: Molecular mechanisms of drug resistance. J Pathol. 2005, 205: 275-292. 10.1002/path.1706.View ArticlePubMedGoogle Scholar
- Lampson MA, Kapoor TM: Unraveling cell division mechanisms with small-molecule inhibitors. Nat Chem Biol. 2006, 2: 19-27. 10.1038/nchembio757.View ArticlePubMedGoogle Scholar
- Edgar BA, Orr-Weaver TL: Endoreplication cell cycles: more for less. Cell. 2001, 105: 297-306. 10.1016/S0092-8674(01)00334-8.View ArticlePubMedGoogle Scholar
- Geng Y, Yu Q, Sicinska E, Das M, Schneider JE, Bhattacharya S, Rideout WM, Bronson RT, Gardner H, Sicinski P: Cyclin E ablation in the mouse. Cell. 2003, 114: 431-443. 10.1016/S0092-8674(03)00645-7.View ArticlePubMedGoogle Scholar
- Lilly MA, Duronio RJ: New insights into cell cycle control from the Drosophila endocycle. Oncogene. 2005, 24: 2765-2775. 10.1038/sj.onc.1208610.View ArticlePubMedGoogle Scholar
- Martindill DM, Risebro CA, Smart N, Franco-Viseras Mdel M, Rosario CO, Swallow CJ, Dennis JW, Riley PR: Nucleolar release of Hand1 acts as a molecular switch to determine cell fate. Nat Cell Biol. 2007, 9: 1131-1141. 10.1038/ncb1633.View ArticlePubMedGoogle Scholar
- Ganier O, Mechali M: New cell or new cycle?. Genes Dev. 2008, 22: 2908-2913. 10.1101/gad.1740808.View ArticlePubMedGoogle Scholar
- Ullah Z, Lee CY, Lilly MA, DePamphilis ML: Developmentally programmed endoreduplication in animals. Cell Cycle. 2009, 8: 1501-1509. 10.4161/cc.8.10.8325.PubMed CentralView ArticlePubMedGoogle Scholar
- Ma HT, Tsang YH, Marxer M, Poon RY: Cyclin A2-cyclin-dependent kinase 2 cooperates with the PLK1-SCFbeta-TrCP1-EMI1-anaphase-promoting complex/cyclosome axis to promote genome reduplication in the absence of mitosis. Mol Cell Biol. 2009, 29: 6500-6514. 10.1128/MCB.00669-09.PubMed CentralView ArticlePubMedGoogle Scholar
- Kim JA, Lee J, Margolis RL, Fotedar R: SP600125 suppresses Cdk1 and induces endoreplication directly from G2 phase, independent of JNK inhibition. Oncogene. 2010, 29: 1702-1716. 10.1038/onc.2009.464.PubMed CentralView ArticlePubMedGoogle Scholar
- Sakaue-Sawano A, Kurokawa H, Morimura T, Hanyu A, Hama H, Osawa H, Kashiwagi S, Fukami K, Miyata T, Miyoshi H, Imamura T, Ogawa M, Masai H, Miyawaki A: Visualizing spatiotemporal dynamics of multicellular cell-cycle progression. Cell. 2008, 132: 487-498. 10.1016/j.cell.2007.12.033.View ArticlePubMedGoogle Scholar
- Nagai T, Ibata K, Park ES, Kubota M, Mikoshiba K, Miyawaki A: A variant of yellow fluorescent protein with fast and efficient maturation for cell-biological applications. Nat Biotechnol. 2002, 20: 87-90. 10.1038/nbt0102-87.View ArticlePubMedGoogle Scholar
- Sakaue-Sawano A, Ohtawa K, Hama H, Kawano M, Ogawa M, Miyawaki A: Tracing the silhouette of individual cells in S/G2/M phases with fluorescence. Chem Biol. 2008, 15: 1243-1248. 10.1016/j.chembiol.2008.10.015.View ArticlePubMedGoogle Scholar
- Shaner NC, Campbell RE, Steinbach PA, Giepmans BN, Palmer AE, Tsien RY: Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. Red fluorescent protein. Nat Biotechnol. 2004, 22: 1567-1572. 10.1038/nbt1037.View ArticlePubMedGoogle Scholar
- Luther Ed, Karnentsky LA: Resolution of Mitotic Cells Using Laser Scanning Cytometry. Cytometry. 1996, 23: 272-278. 10.1002/(SICI)1097-0320(19960401)23:4<272::AID-CYTO2>3.0.CO;2-J.View ArticlePubMedGoogle Scholar
- Liebel U, Starkuviene V, Erfle H, Simpson JC, Poustka A, Wiemann S, Pepperkok R: A microscope-based screening platform for large-scale functional protein analysis in intact cells. FEBS Lett. 2003, 554: 394-398. 10.1016/S0014-5793(03)01197-9.View ArticlePubMedGoogle Scholar
- Kawasaki M, Sasaki K, Satoh T, Kurose A, Kamada T, Furuya T, Murakami T, Todoroki T: Laser scanning cytometry (LSC) allows detailed analysis of the cell cycle in PI stained fuman fibroblasts (TIG-7). Cell Prolif. 1997, 30: 139-147. 10.1111/j.1365-2184.1997.tb00930.x.View ArticlePubMedGoogle Scholar
- Neumann B, Held M, Liebel U, Erfle H, Rogers P, Pepperkok R, Ellenberg J: High-throughput RNAi screening by time-lapse imaging of live human cells. Nat Methods. 2006, 3: 385-390. 10.1038/nmeth876.View ArticlePubMedGoogle Scholar
- Bartfeld S, Hess S, Bauer B, Machuy N, Ogilvie LA, Schuchhardt J, Meyer TF: High-throughput and single-cell imaging of NF-κB oscillations using monoclonal cell lines. BMC Cell Biology. 2010, 11: 21-10.1186/1471-2121-11-21.PubMed CentralView ArticlePubMedGoogle Scholar
- Cortés F, Pastor N: Induction of endoreduplication by topoisomerase II catalytic inhibitors. Mutagenesis. 2003, 18: 105-112.View ArticlePubMedGoogle Scholar
- Jin ZH, Kurosu T, Yamaguchi M, Arai A, Miura O: Hematopoietic cytokines enhance Chk1-dependent G2/M checkpoint activation by etoposide through the Akt/GSK3 pathway to inhibit apoptosis. Oncogene. 2005, 24: 1973-1981. 10.1038/sj.onc.1208408.View ArticlePubMedGoogle Scholar
- Castedo M, Perfettini JL, Roumier T, Valent A, Raslova H, Yakushijin K, Horne D, Feunteun J, Lenoir G, Medema R, Vainchenker W, Kroemer G: Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy. Oncogene. 2004, 23: 4362-4370. 10.1038/sj.onc.1207572.View ArticlePubMedGoogle Scholar
- Erenpreisa J, Kalejs M, Cragg MS: Mitotic catastrophe and endomitosis in tumour cells: an evolutionary key to a molecular solution. Cell Biol Int. 2005, 29: 1012-1018. 10.1016/j.cellbi.2005.10.005.View ArticlePubMedGoogle Scholar
- Mansilla S, Priebe W, Portugal J: Mitotic catastrophe results in cell death by caspase-dependent and caspase-independent mechanisms. Cell Cycle. 2006, 5: 53-60. 10.4161/cc.5.1.2267.View ArticlePubMedGoogle Scholar
- Vogel C, Hager C, Bastians H: Mechanisms of mitotic cell death induced by chemotherapy-mediated G2 checkpoint abrogation. Cancer Res. 2007, 67: 339-345. 10.1158/0008-5472.CAN-06-2548.View ArticlePubMedGoogle Scholar
- Vakifahmetoglu H, Olsson M, Zhivotovsky B: Death through a tragedy: mitotic catastrophe. Cell Death Differ. 2008, 15: 1153-1162. 10.1038/cdd.2008.47.View ArticlePubMedGoogle Scholar
- Zhu G, Conner SE, Zhou X, Shih C, Li T, Anderson BD, Brooks HB, Campbell RM, Considine E, Dempsey JA, Faul MM, Ogg C, Patel B, Schultz RM, Spencer CD, Teicher B, Watkins SA: Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors. J Med Chem. 2003, 46: 2027-2030. 10.1021/jm0256169.View ArticlePubMedGoogle Scholar
- Hoffman RM: The multiple uses of fluorescent proteins to visualize cancer in vivo. Nat Rev Cancer. 2005, 5: 796-806. 10.1038/nrc1717.View ArticlePubMedGoogle Scholar
- Mehrotra S, Maqbool SB, Kolpakas A, Murnen K, Calvi BR: Endocycling cells do not apoptose in response to DNA rereplication genotoxic stress. Genes Dev. 2008, 22: 3158-3171. 10.1101/gad.1710208.PubMed CentralView ArticlePubMedGoogle Scholar
- Bermejo R, Vilaboa N, Calés C: Regulation of CDC6, geminin, and CDT1 in human cells that undergo polyploidization. Mol Biol Cell. 2002, 13: 3989-4000. 10.1091/mbc.E02-04-0217.PubMed CentralView ArticlePubMedGoogle Scholar
- Ang XL, Harper JW: Interwoven ubiquitination oscillators and control of cell cycle transitions. Sci STKE. 2004, 242: pe31-10.1126/stke.2422004pe31.Google Scholar
- García-Higuera I, Manchado E, Dubus P, Cañamero M, Méndez J, Moreno S, Malumbres M: Genomic stability and tumour suppression by the APC/C cofactor Cdh1. Nat Cell Biol. 2008, 10: 802-811.View ArticlePubMedGoogle Scholar
- Nakayama K, Nagahama H, Minamishima YA, Matsumoto M, Nakamichi I, Kitagawa K, Shirane M, Tsunematsu R, Tsukiyama T, Ishida N, Kitagawa M, Nakayama K, Hatakeyama S: Targeted disruption of Skp2 results in accumulation of cyclin E and p27(Kip1), polyploidy and centrosome overduplication. EMBO J. 2000, 19: 2069-2081. 10.1093/emboj/19.9.2069.PubMed CentralView ArticlePubMedGoogle Scholar
- Miyoshi H, Blömer U, Takahashi M, Gage FH, Verma IM: Development of a self-inactivating lentivirus vector. J Virol. 1998, 72: 8150-8157.PubMed CentralPubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.